Pathogenesis of an attenuated and a virulent strain of group A human rotavirus in neonatal gnotobiotic pigs
- PMID: 8757984
- DOI: 10.1099/0022-1317-77-7-1431
Pathogenesis of an attenuated and a virulent strain of group A human rotavirus in neonatal gnotobiotic pigs
Abstract
Gnotobiotic (Gn) pigs were orally inoculated with Wa strain (G1P1A[P8]) human rotavirus (Wa HRV) serially passaged in Gn pigs (virulent) or cell culture (attenuated) to determine the median virus infectious dose (ID50) and to assess the site of infection and type and progression of morphological lesions and clinical responses induced by these two strains in Gn pigs. The ID50 of virulent Wa HRV was = or < 1 f.f.u. whereas the infectivity of attenuated Wa HRV had to be determined by seroconversion and was approximately 1.3 x 1O(6) f.f.u. Diarrhoea developed at 13 h post-inoculation (p.i.) in pigs inoculated with approximately 1O(5) f.f.u. of virulent Wa HRV and correlated with the presence of viral antigen within villous epithelial cells; villous atrophy developed later at 24 h p.i. and correlated with peak faecal viral titres; recovery from disease correlated with the return of morphologically normal villi. Virus, diarrhoea and villous atrophy were not detected in pigs inoculated with approximately 2 x 10(8)f.f.u. attenuated Wa HRV although HRV-specific serum antibodies were present by 7 days p.i. These findings demonstrate that virulent Wa HRV infection in Gn pigs occurs primarily within intestinal villous epithelial cells with villous atrophy developing as a sequela to infection. However, factors other than villous atrophy appear to contribute to the early stages of HRV-associated disease expression in Gn pigs. The ability of the attenuated virus to elicit virus-neutralizing serum antibodies without disease or pathology indicates promise in the use of such strains for oral immunization.
Similar articles
-
Systemic and intestinal antibody responses to NSP4 enterotoxin of Wa human rotavirus in a gnotobiotic pig model of human rotavirus disease.J Med Virol. 2002 Sep;68(1):119-28. doi: 10.1002/jmv.10178. J Med Virol. 2002. PMID: 12210439
-
Viremia and nasal and rectal shedding of rotavirus in gnotobiotic pigs inoculated with Wa human rotavirus.J Virol. 2005 May;79(9):5428-36. doi: 10.1128/JVI.79.9.5428-5436.2005. J Virol. 2005. PMID: 15827157 Free PMC article.
-
Antibody-secreting cell responses to rotavirus proteins in gnotobiotic pigs inoculated with attenuated or virulent human rotavirus.J Clin Microbiol. 2001 Aug;39(8):2807-13. doi: 10.1128/JCM.39.8.2807-2813.2001. J Clin Microbiol. 2001. PMID: 11473996 Free PMC article.
-
The gnotobiotic piglet as a model for studies of disease pathogenesis and immunity to human rotaviruses.Arch Virol Suppl. 1996;12:153-61. doi: 10.1007/978-3-7091-6553-9_17. Arch Virol Suppl. 1996. PMID: 9015112 Review.
-
Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model.Vet Immunol Immunopathol. 2002 Sep 10;87(3-4):147-60. doi: 10.1016/s0165-2427(02)00046-6. Vet Immunol Immunopathol. 2002. PMID: 12072229 Free PMC article. Review.
Cited by
-
Escherichia coli Nissle 1917 protects gnotobiotic pigs against human rotavirus by modulating pDC and NK-cell responses.Eur J Immunol. 2016 Oct;46(10):2426-2437. doi: 10.1002/eji.201646498. Epub 2016 Aug 11. Eur J Immunol. 2016. PMID: 27457183 Free PMC article.
-
Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.Clin Exp Immunol. 2004 Mar;135(3):361-72. doi: 10.1111/j.1365-2249.2004.02395.x. Clin Exp Immunol. 2004. PMID: 15008967 Free PMC article.
-
Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection.Clin Diagn Lab Immunol. 2004 Jan;11(1):12-20. doi: 10.1128/cdli.11.1.12-20.2004. Clin Diagn Lab Immunol. 2004. PMID: 14715539 Free PMC article.
-
Combined Live Oral Priming and Intramuscular Boosting Regimen with Rotarix® and a Nanoparticle-Based Trivalent Rotavirus Vaccine Evaluated in Gnotobiotic Pig Models of G4P[6] and G1P[8] Human Rotavirus Infection.Vaccines (Basel). 2023 May 2;11(5):927. doi: 10.3390/vaccines11050927. Vaccines (Basel). 2023. PMID: 37243031 Free PMC article.
-
The role of the gut microbiota in regulating responses to vaccination: current knowledge and future directions.FEBS J. 2025 Mar;292(6):1480-1499. doi: 10.1111/febs.17241. Epub 2024 Aug 5. FEBS J. 2025. PMID: 39102299 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical